NFKB1 and liver cancer: This would be undesirable, because NF-κB pan-blockade could promote hepatocyte death and liver cancer and offer no advantage over current IKK inhibitors.22–24 Therefore, we performed in vitro kinase assays to test whether P6 inhibits IKK activity.